SpeeDx-SMALL--Master.png
SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test
25 sept. 2018 08h00 HE | SpeeDx Pty Ltd
SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not...
SpeeDx-SMALL--Master.png
UK drafts new M. genitalium guidelines: Resistance Guided Therapy to tackle antibiotic resistance
23 juil. 2018 03h00 HE | SpeeDx Pty Ltd
LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- The British Association of Sexual Health and HIV (BASHH) draft guidelines for the sexually transmitted infection Mycoplasma genitalium (Mgen) were posted...
SpeeDx-SMALL--Master.png
Clinical data demonstrates significantly increased cure rates using Resistance Guided Therapy for treating the STI Superbug M. genitalium
21 juin 2018 03h00 HE | SpeeDx Pty Ltd
SYDNEY, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced clinical data contained in a new study published in the June 2018 issue of Clinical Infectious Diseases1 [ link]...
SpeeDx-SMALL--Master.png
SpeeDx receives FDA clearance for Mycoplasma genitalium product
19 avr. 2018 08h00 HE | SpeeDx Pty Ltd
SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx’s ResistancePlus® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United...
SpeeDx-SMALL--Master.png
SpeeDx Pty. Ltd. establishes US-based operation
04 déc. 2017 08h00 HE | SpeeDx Pty Ltd
SYDNEY, Australia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd, a developer of advanced multiplex molecular diagnostic solutions, announced the incorporation of a US-based subsidiary company,...